Josh Bandopadhay, Pavel S Pichardo-Rojas, Rhea Cho, Elham Tavakkol, Kamand Khalaj, Andres Rodriguez, Antonio Dono, Roy Riascos, Nitin Tandon, Yoshua Esquenazi
{"title":"老年胶质母细胞瘤患者rano切除标准的评估。","authors":"Josh Bandopadhay, Pavel S Pichardo-Rojas, Rhea Cho, Elham Tavakkol, Kamand Khalaj, Andres Rodriguez, Antonio Dono, Roy Riascos, Nitin Tandon, Yoshua Esquenazi","doi":"10.1007/s11060-025-05168-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Elderly patients with IDH-wild type glioblastoma (IDH-WT GBM) have a dismal prognosis compared to younger patients. Given the prognostic relevance of extent of resection (EOR), we aimed to assess the prognostic utility of the Response Assessment in Neuro-Oncology (RANO)-resect classification in this population.</p><p><strong>Methods: </strong>We retrospectively analyzed patients ≥ 65 years who underwent resection for newly diagnosed IDH-WT GBM between 2005 and 2023. EOR was categorized per RANO-resect classifications based on volumetric MRI analysis.</p><p><strong>Results: </strong>Among 147 patients, 54 (36.7%) had Class 1 and 2 resection, 70 (47.6%) had Class 3 resection, and 23 (15.6%) underwent biopsy. The incidence of postoperative neurological and non-neurological complications was comparable across RANO-resect classes. Median overall survival (OS) was significantly longer for Class 1 and 2 resection (16.0 months, 95% CI: 10.4-21.7) versus Class 3 (10.6 months, 95% CI: 9.1-12.1) and biopsy (8.8 months, 95% CI: 4.0-13.5) (p = 0.033). Progression-free survival (PFS) did not differ between groups. Notably, in the adjuvant chemoradiotherapy sensitivity analysis, categorical RANO-resect classes showed no OS differences, but residual CE tumor volume remained independently prognostic of OS (HR = 1.006; 95% CI: 1.001-1.010; p = 0.010).</p><p><strong>Conclusion: </strong>While greater EOR within RANO-resect classes correlated with improved OS and similar safety, adjuvant chemoradiotherapy sensitivity analyses showed no categorical OS differences. However, residual CE tumor volume remained independently prognostic of survival. Further studies are needed to clarify the role of surgery in elderly IDH-WT GBM patients.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"721-729"},"PeriodicalIF":3.1000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of the RANO-resect criteria in elderly patients with glioblastoma.\",\"authors\":\"Josh Bandopadhay, Pavel S Pichardo-Rojas, Rhea Cho, Elham Tavakkol, Kamand Khalaj, Andres Rodriguez, Antonio Dono, Roy Riascos, Nitin Tandon, Yoshua Esquenazi\",\"doi\":\"10.1007/s11060-025-05168-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Elderly patients with IDH-wild type glioblastoma (IDH-WT GBM) have a dismal prognosis compared to younger patients. Given the prognostic relevance of extent of resection (EOR), we aimed to assess the prognostic utility of the Response Assessment in Neuro-Oncology (RANO)-resect classification in this population.</p><p><strong>Methods: </strong>We retrospectively analyzed patients ≥ 65 years who underwent resection for newly diagnosed IDH-WT GBM between 2005 and 2023. EOR was categorized per RANO-resect classifications based on volumetric MRI analysis.</p><p><strong>Results: </strong>Among 147 patients, 54 (36.7%) had Class 1 and 2 resection, 70 (47.6%) had Class 3 resection, and 23 (15.6%) underwent biopsy. The incidence of postoperative neurological and non-neurological complications was comparable across RANO-resect classes. Median overall survival (OS) was significantly longer for Class 1 and 2 resection (16.0 months, 95% CI: 10.4-21.7) versus Class 3 (10.6 months, 95% CI: 9.1-12.1) and biopsy (8.8 months, 95% CI: 4.0-13.5) (p = 0.033). Progression-free survival (PFS) did not differ between groups. Notably, in the adjuvant chemoradiotherapy sensitivity analysis, categorical RANO-resect classes showed no OS differences, but residual CE tumor volume remained independently prognostic of OS (HR = 1.006; 95% CI: 1.001-1.010; p = 0.010).</p><p><strong>Conclusion: </strong>While greater EOR within RANO-resect classes correlated with improved OS and similar safety, adjuvant chemoradiotherapy sensitivity analyses showed no categorical OS differences. However, residual CE tumor volume remained independently prognostic of survival. Further studies are needed to clarify the role of surgery in elderly IDH-WT GBM patients.</p>\",\"PeriodicalId\":16425,\"journal\":{\"name\":\"Journal of Neuro-Oncology\",\"volume\":\" \",\"pages\":\"721-729\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuro-Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11060-025-05168-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05168-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Assessment of the RANO-resect criteria in elderly patients with glioblastoma.
Introduction: Elderly patients with IDH-wild type glioblastoma (IDH-WT GBM) have a dismal prognosis compared to younger patients. Given the prognostic relevance of extent of resection (EOR), we aimed to assess the prognostic utility of the Response Assessment in Neuro-Oncology (RANO)-resect classification in this population.
Methods: We retrospectively analyzed patients ≥ 65 years who underwent resection for newly diagnosed IDH-WT GBM between 2005 and 2023. EOR was categorized per RANO-resect classifications based on volumetric MRI analysis.
Results: Among 147 patients, 54 (36.7%) had Class 1 and 2 resection, 70 (47.6%) had Class 3 resection, and 23 (15.6%) underwent biopsy. The incidence of postoperative neurological and non-neurological complications was comparable across RANO-resect classes. Median overall survival (OS) was significantly longer for Class 1 and 2 resection (16.0 months, 95% CI: 10.4-21.7) versus Class 3 (10.6 months, 95% CI: 9.1-12.1) and biopsy (8.8 months, 95% CI: 4.0-13.5) (p = 0.033). Progression-free survival (PFS) did not differ between groups. Notably, in the adjuvant chemoradiotherapy sensitivity analysis, categorical RANO-resect classes showed no OS differences, but residual CE tumor volume remained independently prognostic of OS (HR = 1.006; 95% CI: 1.001-1.010; p = 0.010).
Conclusion: While greater EOR within RANO-resect classes correlated with improved OS and similar safety, adjuvant chemoradiotherapy sensitivity analyses showed no categorical OS differences. However, residual CE tumor volume remained independently prognostic of survival. Further studies are needed to clarify the role of surgery in elderly IDH-WT GBM patients.
期刊介绍:
The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.